IHAM
PMVP icon

Integral Health Asset Management’s PMV Pharmaceuticals PMVP Stock Holding History

Integral Health Asset Management’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-50,000
Closed -$1.04M – 81
2022
Q1 		$1.04M Buy
+50,000
New +$882K 0.27% 64

Other funds holding PMVP

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Integral Health Asset Management's PMVP Position: Q2 2022 in Review

Integral Health Asset Management sold out of PMV Pharmaceuticals (PMVP) in Q2 2022, closing a stake of 50,000 shares — an estimated $1.04M sold.

Integral Health Asset Management first reported a position in PMVP in Q1 2022 and held it in 1 quarter. The position peaked at $1.04M in Q1 2022. 105 funds tracked by Wall St. Rank hold PMVP as of Q2 2022.

  • Integral Health Asset Management reported no remaining PMV Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Integral Health Asset Management sold 50,000 PMV Pharmaceuticals shares in Q2 2022, an estimated $1.04M.
  • Integral Health Asset Management first reported a position in PMV Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Integral Health Asset Management's PMV Pharmaceuticals position peaked at $1.04M in Q1 2022.
  • 105 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2022.

Based on Integral Health Asset Management's 13F filing for Q2 2022, filed 3 Aug 2022.